Poster Session 3-6 PNH/Hemolytic anemia

[PS3-6-7] Ravulizumab (ALXN1210) vs eculizumab in complement inhibitor-naive adult patients with PNH

Ken Ishiyama¹, Jong Wook Lee², Scott T. Rottinghaus³, Lily Wong Lee Lee⁴, Viviani Pessoa⁵, Sandra Gualandro⁶, Wolfgang Fureder⁷, Vadim Ptushkin⁸, Flore Sicre De Fontbrune⁹, Lori Volles³, Andrew I Damokosh³, Rasha Aguzzi¹⁰, Rajendra Pradhan³, Stephan Ortiz³, Hubert Schrezenmeier¹¹, Anita Hill¹² (1.Hematology, Kanazawa University Hospital, Ishikawa, Japan, 2.Seoul St. Mary's Hospital, Seoul, South Korea, 3.Alexion Pharmaceuticals, Inc., New Haven, CT, USA, 4.Hematology Unit, Queen Elizabeth Hospital, Kota Kinabalu, Sabah, Malaysia, 5.Hematology, Hemorio, Rio de Janeiro, Brazil, 6.University of Sao Paulo Medical School, Sao Paulo, Brazil, 7.Division of Hematology & Hemostaseology, Medical University of Vienna, Austria, 8.S.P. Botkin Hospital, Moscow, Russia, 9.Hospital Saint-Louis, Paris, France, 10.Alexion Pharmaceuticals, Inc., Lexington, MA, USA, 11.Institute of Transfusion Medicine, University of Ulm, German, 12.Department of Haematology, Leeds Teaching Hospitals, Leeds, UK)